Blood test may predict drug side effects in leukemia patients
NCT ID NCT07254312
First seen Jan 09, 2026 · Last updated May 08, 2026 · Updated 13 times
Summary
This study looks at whether the amount of venetoclax in the blood is linked to serious side effects in people with acute myeloid leukemia (AML) who are in remission. Researchers will measure drug levels in 14 patients and track how often severe low white blood cell counts occur. The goal is to find ways to better manage treatment and keep patients healthy longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione IRCCS Policlinico San Matteo, SC Oncologia
RECRUITINGPavia, Pavia, 27100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.